SEC Comment Letter 0000000000-23-013658 to Harpoon Therapeutics, Inc. (CIK 0001708493)
Harpoon Therapeutics, Inc. (CIK 0001708493)
Date: Dec. 14, 2023 · CIK: 0001708493 · Accession: 0000000000-23-013658
AI Filing Summary & Sentiment
File numbers found in text: 333-275958
Letter
United States securities and exchange commission logo December 14, 2023 Julie Eastland President and Chief Executive Officer Harpoon Therapeutics, Inc. 611 Gateway Boulevard, Suite 400 South San Francisco, California 94080 Re:Harpoon Therapeutics, Inc. Registration Statement on Form S-3 Filed December 8, 2023 File No. 333-275958 Dear Julie Eastland: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marina Remennik
Show Raw Text
United States securities and exchange commission logo
December 14, 2023
Julie Eastland
President and Chief Executive Officer
Harpoon Therapeutics, Inc.
611 Gateway Boulevard, Suite 400
South San Francisco, California 94080
Re:Harpoon Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 8, 2023
File No. 333-275958
Dear Julie Eastland:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marina Remennik